<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754351</url>
  </required_header>
  <id_info>
    <org_study_id>CT/08.01</org_study_id>
    <nct_id>NCT00754351</nct_id>
  </id_info>
  <brief_title>Docetaxel, Gemcitabine and Bevacizumab for Metastatic Breast Cancer</brief_title>
  <official_title>Docetaxel, Gemcitabine and Bevacizumab as Salvage Therapy for Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Crete</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Crete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and toxicity of docetaxel, gemcitabine and bevacizumab&#xD;
      combination, administered biweekly, as salvage treatment in patients with metastatic and HER2&#xD;
      negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Docetaxel plus gemcitabine is an active combination in the salvage treatment for metastatic&#xD;
      breast cancer. Administered every two weeks, this combination has a favorable toxicity&#xD;
      profile, and promising activity in &gt; 1st line treatment for metastatic breast cancer.&#xD;
      Recently, initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab&#xD;
      demonstrated prolonged progression-free survival, as compared with paclitaxel alone. This&#xD;
      study will evaluate the addition of bevacizumab to a biweekly regimen of docetaxel and&#xD;
      gemcitabine in the salvage therapy for metastatic breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>21 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>Assessment every two cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bevacizumab-&gt;Docetaxel-&gt;Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically- or cytologically- confirmed metastatic breast adenocarcinoma&#xD;
&#xD;
          -  No HER2 overexpression or gene amplification&#xD;
&#xD;
          -  At least one previous chemotherapy regimen for metastatic breast cancer&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Performance status (WHO) 0-2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Measurable disease as defined by at least 1 bidimensionally measurable lesion ≥ 20 X&#xD;
             10 mm&#xD;
&#xD;
          -  Performance status (WHO) 0-2&#xD;
&#xD;
          -  Adequate liver function (serum bilirubin &lt;1.5 times the upper normal limit, AST and&#xD;
             ALT &lt;2.5 times the upper normal limit in the absence of demonstrable liver metastases,&#xD;
             or &lt;5 times the upper normal limit in the presence of liver metastases), adequate&#xD;
             renal function (serum creatinine &lt;1.5 times the upper normal limit) and bone marrow ≥&#xD;
             1,500/mm3, PLT ≥ 100,000/mm3, Hgb ≥ 9 g/dL) function&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Progressive brain metastases according to clinical or radiological criteria&#xD;
&#xD;
          -  Brain metastases without prior radiation therapy&#xD;
&#xD;
          -  Radiation therapy within the previous 4 weeks&#xD;
&#xD;
          -  Previous radiation therapy to the only measurable lesion&#xD;
&#xD;
          -  Proteinuria ≥ 500 mgr of protein daily&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Documented hemorrhagic diathesis or coagulation disorder&#xD;
&#xD;
          -  Cardiovascular disease (class II-IV NYHA congestive heart failure, myocardial&#xD;
             infarction within the previous 4 months, unstable angina, LVEF &lt; normal, ventricular&#xD;
             arrhythmia, uncontrolled hypertension)&#xD;
&#xD;
          -  Thrombotic event within the previous 6 months&#xD;
&#xD;
          -  Concurrent use of aspirin &gt; 325 mgr daily, low molecular weight heparin in therapeutic&#xD;
             dose, warfarin or acenocoumarol, non-steroid anti-inflammatory agents&#xD;
&#xD;
          -  Major surgical procedure within the previous 4 weeks&#xD;
&#xD;
          -  Presence of nonhealing wound or fracture&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 2 according to the NCI CTCAE (version 3.0)&#xD;
&#xD;
          -  Any sustained chronic toxicity &gt; grade 2 according to the NCI CTCAE (version 3.0)&#xD;
&#xD;
          -  Uncontrolled infection&#xD;
&#xD;
          -  Any serious, uncontrolled comorbidity on the investigator's judgment&#xD;
&#xD;
          -  Other cancer within the previous 5 years, except non-melanoma skin cancer and in situ&#xD;
             cervical cancer&#xD;
&#xD;
          -  Serious psychiatric illness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitris Mavrudis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Crete, Dep of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Crete, Dep of Medical Oncology</name>
      <address>
        <city>Heraklion</city>
        <state>Crete</state>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alexandroupolis, Dep of Medical Oncology</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>September 17, 2008</study_first_submitted>
  <study_first_submitted_qc>September 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 18, 2008</study_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Crete</investigator_affiliation>
    <investigator_full_name>Vassilis Georgoulias, MD</investigator_full_name>
    <investigator_title>Prof. D. Mavroudis</investigator_title>
  </responsible_party>
  <keyword>docetaxel</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

